Immunovia AB (publ)

Immunovia's capital structure is characterized by a low debt-to-equity ratio of 0.2, indicating a conservative leverage profile. The company holds substantial cash and equivalents of 51.18 million SEK, which is significantly higher than its total liabilities of 27.33 million SEK, resulting in a current ratio of 2.03. This liquidity position supports operational flexibility but does not currently include long-term debt obligations.

Profitability metrics show a challenging performance, with a return on equity of -6.74% and a return on assets of -4.15%. These figures are well below the typical thresholds for sustainable performance in the healthcare equipment and technology industry, where positive returns are generally expected to justify R&D and commercialization investments.

The company's revenue is concentrated in a single business segment focused on diagnostic solutions, with no disclosed geographic diversification. This lack of segment or geographic diversification increases exposure to market-specific risks, particularly in the early-stage diagnostic testing market.

Growth trajectory is constrained, with a reported revenue of 156 million SEK and a significant operating loss of 24.16 million SEK. Analysts project a modest revenue increase to 4 million SEK, but this is inconsistent with the company's current revenue scale and does not reflect meaningful growth. The negative operating cash flow of 24.42 million SEK further limits reinvestment capacity.

Risk factors include a low liquidity risk and low dilution potential, with no immediate filing-based flags detected. However, the company's negative net income and operating cash flow suggest ongoing financial stress. The absence of capital expenditures and the lack of a clear path to profitability raise concerns about long-term sustainability.

Recent events include a consistent EPS estimate of -0.10 SEK, with the last actual EPS at -0.32 SEK, indicating a widening loss per share. The uniformity of analyst price targets at 0.48 SEK suggests limited upside potential in the near term, with no divergence in expectations.

Analysts project 156.4% upside to a consensus price target of 0.48 SEK, significantly above the current market price of 0.1872 SEK.

Operating income improved by 63.1% year-over-year to -109.4 million SEK, indicating a meaningful reduction in operational losses.

Free cash flow improved by 76.3% year-over-year to -69.7 million SEK, demonstrating enhanced cash generation efficiency.

The company maintains a low debt-to-equity ratio of 0.2, which is below the cohort median of 0.11.

Cash conversion metrics rank as best-in-class at 8.29, significantly outperforming the cohort median of 0.82.

The company remains unprofitable with a net loss of 76.5 million SEK and a negative net margin of -18.9%.

Operating margin of -154.9% places the company in the bottom quartile compared to 191 peers in the cohort.

Gross profit remains negative at -64.5 million SEK, highlighting fundamental challenges in core product economics.

Revenue kr 354.0k, −22,2% YoY; Operating income +45,6% YoY.

• ▍Revenue kr 354.0k, −22,2% YoY
• ▍Operating income +45,6% YoY
• ▍Net income −664,4% YoY
• ▍Free cash flow −482,6% YoY
• ▍Net margin -4894.9%

Revenue kr 101.0k, −57,0% YoY; Operating income +19,8% YoY.

• ▍Revenue kr 101.0k, −57,0% YoY
• ▍Operating income +19,8% YoY
• ▍Net income +41,8% YoY
• ▍Free cash flow +19,9% YoY
• ▍Net margin -29450.5%

Revenue kr 90.0k, +5,9% YoY; Operating income +16,1% YoY.

• ▍Revenue kr 90.0k, +5,9% YoY
• ▍Operating income +16,1% YoY
• ▍Net income −60,4% YoY
• ▍Free cash flow −69,7% YoY
• ▍Net margin -45613.3%

Revenue kr 139.0k, −10,9% YoY; Operating income +21,7% YoY.

• ▍Revenue kr 139.0k, −10,9% YoY
• ▍Operating income +21,7% YoY
• ▍Net income −1 861,7% YoY
• ▍Free cash flow −167 491,2% YoY
• ▍Net margin -41577.0%

Revenue kr 685.0k, −26,4% YoY; Operating income +26,5% YoY.

• ▍Revenue kr 685.0k, −26,4% YoY
• ▍Operating income +26,5% YoY
• ▍Net income −90,6% YoY
• ▍Free cash flow −114,0% YoY
• ▍Net margin -21301.5%

Revenue kr 1.1M, +35,7% YoY; Operating income −14,7% YoY.

• ▍Revenue kr 1.1M, +35,7% YoY
• ▍Operating income −14,7% YoY
• ▍Net income −7,8% YoY
• ▍Free cash flow +13,9% YoY
• ▍Net margin -14680.5%

Revenue kr 844.0k; Operating income -kr 166.6M.

• ▍Revenue kr 844.0k
• ▍Operating income -kr 166.6M
• ▍Net margin -18479.4%